<![CDATA[Opening Remarks and the Frontline Treatment Landscape in Advanced HCC]]>
Trending
- Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma
- A pro-inflammatory metastasis-associated macrophage subset induces tumor-promoting mesothelial cell conversion in ovarian cancer via IL-1α secretion
- Scientists find a way to break pancreatic cancer’s protective shield
- Perioperative Durvalumab Combo Boosts Survival in Resectable Gastric Cancer
- Targeting mitochondrial dysfunction and apoptosis in 5-fluorouracil–induced cardiotoxicity using kaempferol-mediated selenium nanoparticles
- Guernsey mum keeping son’s memory alive after brain tumour death
- Stourbridge gran says she remains positive despite her third cancer diagnosis in 15 years
- Circular RNA MCM3 recruits USP49 to stabilize PTBP1 and promote cisplatin resistance in cervical squamous cell carcinoma

![<![CDATA[Opening Remarks and the Frontline Treatment Landscape in Advanced HCC]]> Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG-3 can reverse checkpoint inhibitor resistance.](https://news.shareyourcancerstories.com/wp-content/uploads/2026/06/ltCDATAReviewing-the-HIMALAYA-Trial-of-Tremelimumab-Plus-Durvalumab-in-Unresectable-768x432.png)